Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference

2022-09-27
REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Richard Beckman, M.D., chief medical officer of Adverum Biotechnologies, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. The on-demand webcast corporate presentation may be

Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

2022-09-23
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under Events and Pr

Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation

2022-09-23
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022

2022-09-23
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day a

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

2022-09-15
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

2022-09-14
LUNA Phase 2 Study in Wet AMD - Study Design Objective: The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 study evaluating a one-time IVT injection of either of two doses of Ixo-vec (ADVM-022), including 2x10^11 vg/eye (2E11) dose and a new, lower 6x10^10 vg/eye (6E10) dose in 72 patients. - LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring fr

Adverum Biotechnologies announces first subject dosed in LUNA Phase 2 trial

2022-09-14
Adverum Biotechnologies a... ADVM

Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

2022-09-08
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022. The on-demand webcast corporate presentation may be ac

Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

2022-08-29
REDWOOD CITY, Calif. - Adverum Biotechnologies, Inc. , a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced that... | August 29, 2022

Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Prometheus Biosciences (RXDX) and Adverum Biotechnologies (ADVM)

2022-08-12
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cardinal Health (<span class='tr-stock-ticker' style='color:blue;...